The distinction between receptor-positive (Normal like, Luminal A, Luminal B, and HER-2 positive) and receptor-negative (TNBC or basal like) subtypes of breast cancer has been made using gene expression profiling, in addition to histological subtypes (Kakudji et al., 2021). This evidence concerns the gene ERBB2 and breast carcinoma.